Why the study?
To provide researchers with information and dataset on small molecules in active clinical trials to accelerate research into effective therapies for COVID-19.
What is the clinical progress of small molecule therapies in active clinical trials for the treatment of COVID-19?
What is the clinical progress of small molecule therapies in active clinical trials for the treatment of COVID-19?
This review provides a comprehensive summary of small molecule therapies in active clinical trials for COVID-19 to accelerate research programs.
Answers are grounded in this paper and cite their sources.
Catalogs active small-molecule COVID-19 candidates by class; leaves open which will demonstrate clinical efficacy in ongoing trials.
The coronavirus disease-19 (COVID-19) pandemic has become a global threat since its first outbreak at the end of 2019. Several review articles have been published recently, focusing on the aspects of target biology, drug repurposing, and mechanisms of action (MOAs) for potential treatment. This review gathers all small molecules currently in active clinical trials, categorizes them into six sub-classes, and summarizes their clinical progress. The aim is to provide the researchers from both pharmaceutical industries and academic institutes with the handful information and dataset to accelerate their research programs in searching effective small molecule therapy for treatment of COVID-19.
No takes yet. Share an insight, caveat, or question.
Hu et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: